Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F17%3A00074352" target="_blank" >RIV/65269705:_____/17:00074352 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.026714" target="_blank" >https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.026714</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1161/CIRCULATIONAHA.116.026714" target="_blank" >10.1161/CIRCULATIONAHA.116.026714</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Popis výsledku v původním jazyce

Atrial fibrillation (AF) and valvular heart disease frequently coexist and independently increase mortality.1 Bioprosthetic valve implantation (surgical or transcatheter) is a common, increasingly utilized treatment for valvular heart disease.2 Patients with AF and bioprosthetic valves require anticoagulation to prevent thromboembolic events. Non-vitamin K oral anticoagulants are safe and efficacious alternatives to vitamin K antagonists for anticoagulation in AF. However, guidelines recommend against using non-vitamin K oral anticoagulants in patients with bioprosthetic valves, citing a lack of supporting data. Only 1 of the first 3 warfarin-controlled pivotal non-vitamin K oral anticoagulants trials in AF included patients with bioprosthetic valves (n&gt;80).3 The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation Thrombolysis in Myocardial Infarction 48), which compared edoxaban (a direct oral factor Xa inhibitor) to warfarin in patients with AF,4 did not exclude patients with bioprosthetic valves, thus providing an opportunity to analyze this high-risk subgroup.

Název v anglickém jazyce

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Popis výsledku anglicky

Atrial fibrillation (AF) and valvular heart disease frequently coexist and independently increase mortality.1 Bioprosthetic valve implantation (surgical or transcatheter) is a common, increasingly utilized treatment for valvular heart disease.2 Patients with AF and bioprosthetic valves require anticoagulation to prevent thromboembolic events. Non-vitamin K oral anticoagulants are safe and efficacious alternatives to vitamin K antagonists for anticoagulation in AF. However, guidelines recommend against using non-vitamin K oral anticoagulants in patients with bioprosthetic valves, citing a lack of supporting data. Only 1 of the first 3 warfarin-controlled pivotal non-vitamin K oral anticoagulants trials in AF included patients with bioprosthetic valves (n&gt;80).3 The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation Thrombolysis in Myocardial Infarction 48), which compared edoxaban (a direct oral factor Xa inhibitor) to warfarin in patients with AF,4 did not exclude patients with bioprosthetic valves, thus providing an opportunity to analyze this high-risk subgroup.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Circulation

ISSN

0009-7322

e-ISSN

—

Svazek periodika

135

Číslo periodika v rámci svazku

13

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

3

Strana od-do

1273-1275

Kód UT WoS článku

000397387200020

EID výsledku v databázi Scopus

—